Pharmacotherapeutic group: 'other topical product for joint and muscular pain, combinations'
ATC vet code: QM02AX99
Pharmacodynamic properties
Prednisolone is a synthetic glucocorticoid with anti-inflammatory action. It has anti-exudative properties and an anti-granulomatous action. It decreases the fibroblastic reaction by stabilising the cell membranes and prevents cellular destruction and therefore inflammation of the treated area. In addition, it increases local vascular tonus and decreases oedema. Finally, it prevents the depolymerisation of mucopolysaccharides.
Lidocaine is a local anaesthetic.
Dimethyl sulfoxide (DMSO) improves the transcutaneous penetration of the active ingredients by increasing cellular permeability.
Pharmacokinetic particulars
No specific information is available following cutaneous application of the combination product to horses.
When applied topically to intact skin, lidocaine is subject to limited and delayed absorption. Greater absorption of lidocaine should be expected in cases of compromised skin barrier function. Lidocaine is cleared by hepatic metabolism to active and inactive metabolites, then excreted via the kidneys. Terminal half-life is less than 2 hours in most animal species.
When applied topically to intact skin, prednisolone is subject to limited and delayed absorption. Greater absorption of prednisolone should be expected in cases of compromised skin barrier function. Metabolism occurs at both hepatic and extrahepatic (including the kidney) sites. Terminal half-life in horses is about 3 hours. The parent drug and its metabolites are excreted in the urine.